Drug firm Lupin today posted an increase of 42.57% in its consolidated net profit to Rs 335.2 crore for the third quarter ended December 31, 2012, on the back of strong sales in the US market.
The Mumbai-headquartered firm had posted a net profit of Rs 235.1 crore during the same period of previous fiscal.
Consolidated net sales of the company rose by 37.62% to Rs 2,465.9 crore during the third quarter, as against Rs 1,791.7 crore during the same period of 2011-12 fiscal, Lupin Ltd said in a statement.
"We had a record quarter driven by strong operating performance and growth in the US. Importantly, we continue to improve on margins consistently," Lupin Ltd Managing Director Kamal K Sharma said.
Shares of Lupin were trading at Rs 608.15 apiece on the BSE in late afternoon trade, up 1.49% from their previous close.
